Gottfried E. Konecny, MD

Articles

Endometrial Cancer: Future Directions and Unmet Needs

July 31st 2025

Panelists discuss how emerging antibody-drug conjugates targeting B7-H4 and folate receptors are showing unprecedented 40% to 50% response rates in recurrent endometrial cancer, representing a paradigm shift from historical treatment limitations while highlighting the exciting but challenging landscape of sequencing multiple novel therapies.

Optimizing Therapy for MMR-Proficient Endometrial Cancer

July 31st 2025

Panelists discuss how the DUO trial demonstrates the benefit of durvalumab in adjuvant endometrial cancer treatment and suggests potential value of adding olaparib in specific subgroups like mismatch repair–proficient patients, though emphasizing the need for confirmatory studies before routine clinical implementation.

Ongoing Research to Watch in Ovarian Cancer in 2025 and Beyond

July 29th 2025

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss ongoing research to watch in ovarian cancer.

RUBY Trial: Real-World Safety, Efficacy Analysis, and Quality of Life Considerations in Endometrial Cancer

July 24th 2025

Panelists discuss how the RUBY trial’s real-world data confirms the efficacy of dostarlimab maintenance therapy and surprisingly shows improved quality of life outcomes with delayed time to deterioration compared to placebo, providing confidence in using immunotherapy maintenance despite potential adverse effects.

SIENDO Study: Long-Term Safety and Efficacy of Selinexor Maintenance in Endometrial Cancer

July 24th 2025

Panelists discuss how selinexor shows remarkable efficacy in patients with mismatch repair–proficient endometrial cancer, with 40-month progression-free survival compared to 5 months with standard care, while emphasizing the importance of ongoing clinical trials to validate biomarker-driven treatment decisions.

Findings for Neoadjuvant IMNN-001 Plus Chemo in Newly Diagnosed, Advanced Epithelial Ovarian Cancer

July 22nd 2025

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for neoadjuvant IMNN-001 plus chemotherapy in advanced epithelial ovarian cancer.

Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer: The ROSELLA Trial

July 17th 2025

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Biomarker Testing and Treatment Selection in Advanced Endometrial Cancer

July 17th 2025

Panelists discuss how endometrial cancer treatment has been revolutionized through molecular subtyping into 4 distinct groups (POLE hypermutated, microsatellite instability-high, p53 mutated, and no specific molecular pathology), enabling personalized treatment approaches based on tumor biology rather than just staging.

Advanced Cervical Cancer: Novel Immunotherapy Combinations and Future Treatment Paradigms

July 17th 2025

Panelists discuss how the field is expanding with newer antibody-drug conjugates targeting TROP2, combination immunotherapy approaches, and the critical importance of HPV vaccination as prevention, while addressing social barriers to complex treatment regimens.

TRUST Trial: Outcomes With Radical Up-Front Surgery in Advanced Ovarian Cancer

July 15th 2025

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for radical up-front surgery in advanced ovarian cancer from the TRUST trial.

ADC Treatment Strategies in Cervical Cancer: Clinical Implementation and Emerging Treatment Options

July 10th 2025

Panelists discuss how tisotumab vedotin represents a practice-changing but modest improvement in cervical cancer treatment, with only 1.5-month progression-free survival benefit and notable ocular toxicities, while emphasizing the need for better patient access to required ophthalmologic monitoring.

Advanced Cervical Cancer Treatment Landscape: Clinical Decision-Making and Biomarker Integration

July 10th 2025

Panelists discuss how cervical cancer treatment guidelines have rapidly evolved to incorporate pembrolizumab across multiple settings, from locally advanced disease with positive nodes to metastatic disease, while emphasizing the importance of comprehensive biomarker testing including PD-L1 and HER2 status for optimal treatment selection.

Recent Advances and Future Direction in Ovarian Cancer Treatments

July 1st 2025

Panelists discuss how the recent approval of avutometinib plus defactinib for KRAS-mutated low-grade serous ovarian cancer addresses a significant unmet need in this lethal disease, with the dual FAK/MEK inhibition approach showing impressive response rates despite requiring careful toxicity management.

The Evolving Ovarian Cancer ADC Landscape

July 1st 2025

Panelists discuss how the emerging pipeline of folate receptor-targeted antibody-drug conjugates, including rinatabart sesutecan (Rina-S) and other novel compounds, offers diverse payload options and potentially broader patient eligibility with different toxicity profiles, though sequencing strategies remain to be determined.

Data for First-Line Dostarlimab and Niraparib in Advanced Ovarian Cancer: The FIRST Trial

June 26th 2025

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss data for dostarlimab plus niraparib in advanced ovarian cancer.

Mirvetuximab Soravtansine in Advanced Ovarian Cancer: Survival Benefits, Quality of Life, and Ocular Toxicity Management

June 24th 2025

Panelists discuss how mirvetuximab soravtansinerepresents a significant advancement for platinum-resistant ovarian cancer with folate receptor alpha expression, providing unprecedented overall survival benefits despite manageable ocular toxicities that are reversible with proper monitoring and dose modifications.

Evolving Maintenance Approaches: Clinical Trial Updates in Ovarian Cancer

June 24th 2025

Panelists discuss how the frontline immunotherapy landscape is evolving with promising but not yet practice-changing data from the KEYNOTE and FIRST trials, suggesting potential benefits when combining pembrolizumab with PARP inhibitors in specific biomarker-defined subgroups of patients with ovarian cancer.

Antibody-Drug Conjugates Could Continue to Reshape Ovarian Cancer Management

June 19th 2025

Tara Berman, MD, MS, and Gottfried E. Konecny, MD, discuss how ADCs could continue to reshape ovarian cancer management.

Navigating Frontline Maintenance Options for Advanced Ovarian Cancer

June 17th 2025

Panelists discuss how NCCN guidelines structure treatment options for advanced ovarian cancer around bevacizumab decisions and HRD status, with most experts favoring PARP inhibitor maintenance therapy for 2 to 3 years while carefully monitoring for long-term toxicities like MDS and secondary leukemias.

Biomarker-Driven Treatment Selection in Advanced Ovarian Cancer

June 17th 2025

Panelists discuss how molecular testing approaches in advanced ovarian cancer should include comprehensive upfront biomarker assessment including HRD testing, folate receptor testing, PD-L1, and HER2 evaluation, combined with germline genetic counseling to guide treatment decisions and maintenance therapy strategies.